The findings showed that the obesity rate in the United States decreased from 46.2% in 2021 to 45.6% in 2023. This marks the first decline in the obesity rate in a decade, a significant milestone in the ongoing battle against obesity in the country.
The study, conducted by researchers at Harvard University, analyzed data on almost 17 million adults nationwide. Obesity was defined as having a body mass index (BMI) of 30 or above. The researchers noted that the most significant decrease in obesity was observed in the South, which also had the highest dispensing rate of GLP-1 medications.
GLP-1 medications, such as Wegovy and Zepbound, have seen a surge in use in recent years. These medications have been associated with weight loss, although the researchers cautioned that it is not possible to confirm a cause-and-effect relationship between the decline in obesity rates and the increased use of these medications.
The study, led by Benjamin Rader, an assistant professor of anesthesia at Harvard Medical School, was published in the journal JAMA Health Forum. Rader and his team highlighted the long-standing issue of rising obesity rates in the U.S. and the conflicting forecasts about whether this trend will continue or plateau.
The introduction of GLP-1 medications into the market has introduced a new factor in the fight against obesity. These medications, which mimic a hormone in the intestine that helps regulate appetite, have shown promising results in terms of weight loss. Sales of these medications have soared in recent years, and many individuals have experienced significant weight loss as a result.
The study tracked health insurance data from 2013 through 2023 and focused on adults between the ages of 26 and 75. While the researchers were unable to definitively establish a causal relationship between the decline in obesity rates and the use of GLP-1 medications, the findings suggest that these medications may play a role in addressing the obesity epidemic in the U.S.
Overall, the study provides valuable insights into the complex factors influencing obesity rates in the U.S. and underscores the need for continued research and intervention to combat this ongoing public health challenge.
